Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom
DLBCL
DRUG: Tafasitamab|DRUG: Lenalidomide|DRUG: Gemcitabine|DRUG: Oxaliplatin|DRUG: Rituximab
Dose limiting toxicity（DLT）and other adverse events (AEs) of tafasitamab and lenalidomide in combination with GemOx (TL-GemOx) assessed using CTCAE v5.0, within 28 days after therapy initiation|PFS assessed by IRC according to Lugano 2014, 1-3 years approximately
Objective Response Rate (ORR) according to investigator., 1-3 years approximately|Complete Response Rate (CRR) according to investigator., 1-3 years approximately|Duration of Response (DOR) according to investigator., 1-3 years approximately|Progression free survival (PFS) assessed by investigator according to the Lugano 2014, 1-3 years approximately|Time to response (TTR), 1-3 years approximately|Overall Survival (OS), 1-3 years approximately|Time to next treatment (TTNT), 1-3 years approximately|Adverse events assessed by CTCAE version 5.0 criteria., 1-3 years approximately|Quality of life assessment: Patient-reported outcomes (PROs) on happiness and general health status based on Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym), 1-3 years approximately|Quality of life assessment: Patient-reported outcomes (PROs) on happiness and general health status based on EuroQol five dimensions questionnaire (EQ-5D-5L), 1-3 years approximately
This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom